Bioceres price target lowered to $25 from $30 at Lake Street

Lake Street lowered the firm’s price target on Bioceres to $25 from $30 and keeps a Buy rating on the shares after the company reported Q4 results below the firm’s estimates. Bioceres “continues to represent our highest conviction long-term small-cap agriculture investment,” but reported “a third straight uneven quarterly result” and faces “persistently low volume in the stock” that reduces near term upside potential, the analyst tells investors.